Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

SHOCKING: Bioxcel - What They Never Told You

1 Top Penny Stock to Watch Now

This small-cap biotech is chasing a big breakthrough in 2026.

BioXcel Drug Calms Agitation At Home For Schizophrenia, Bipolar Patients

BioXcel Drug Calms Agitation At Home For Schizophrenia, Bipolar Patients

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) on Wednesday released topline exploratory efficacy data from the SERENITY At-Home Pivotal Phase 3 safety trial, which demonstrated that BXCL501 had continued effects and consistent benefit with repeat dosing.

BioXcel Therapeutics (BTAI) Stock Is Surging Monday: What's Going On?

BioXcel Therapeutics (BTAI) Stock Is Surging Monday: What's Going On?

BioXcel Therapeutics Inc (NASDAQ:BTAI) shares are trading higher. The AI biopharmaceutical company on Monday announced positive meeting comments from the U.S. Food and Drug Administration (FDA).

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

BioXcel Therapeutics (BTAI) Stock Is Extremely Volatile Today: What's Going On?

Shares of BioXcel Therapeutics Inc (NASDAQ:BTAI) are trading higher Tuesday morning, reversing sharply following earlier weakness, after the company announced its financial results for the second quarter. Here’s what investors need to know.

BTAI: SERENITY III Trial to Initiate in 2H22…

By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT

Oaktree, Qatar Investment Inject $260M In BioXcel To Fund Commercialization Of Schizophrenia Med

BioXcel Therapeutics Inc (NASDAQ:BTAI) received strategic financing from Oaktree Capital Management and Qatar Investment Authority (QIA) for gross funding of $260 million. The Company will use the funding to support the commercial activities of Igalmi (dexmedetomidine) sublingual film indicated for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder.…

Why BioXcel Therapeutics Stock Is Surging Today

BioXcel Therapeutics Inc (NASDAQ: BTAI) shares are trading higher Wednesday after the company announced that the U.S.

inkl

Read news from The Economist, FT, and more,
with one subscription

FDA Approves BioXcel's Igalmi - First Orally Dissolving Sublingual Film For Schizophrenia-Associated Agitation

FDA Approves BioXcel's Igalmi - First Orally Dissolving Sublingual Film For Schizophrenia-Associated Agitation

The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy

The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy

Here's a roundup of top developments in the biotech space over the last 24 hours.

The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel

The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel

Here's a roundup of top developments in the biotech space over the last 24 hours:

BTAI: Final Countdown to April 5, 2022 PDUFA Date for BXCL501…

By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT

BioXcel BXCL701 Combo Therapy Shows Encouraging Response Rates In Prostate Cancer

BioXcel BXCL701 Combo Therapy Shows Encouraging Response Rates In Prostate Cancer

BioXcel Therapeutics Inc (NASDAQ: BTAI) announced results from its ongoing Phase 2 trial of BXCL701 in metastatic castration-resistant prostate cancer (mCRPC) patients with either adenocarcinoma or small cell neuroendocrine carcinoma (SCNC) phenotype.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Qatar Investment Authority

Oaktree Capital Management

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

415,638 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play